• American Medical Directors Association (AMDA). Pharmacotherapy companion to the depression clinical practice guideline. Columbia (MD): American Medical Directors Association (AMDA); 2005. 24 p. [12 references]

This is the current release of the guideline.

This guideline updates a previous version: Pharmacotherapy companion to the depression clinical practice guideline. Columbia (MD): American Medical Directors Association; 1998. 26 p.

The type of evidence supporting the recommendations is not specifically stated.

The guideline was developed by an interdisciplinary workgroup, using a process that combined evidence- and consensus-based approaches. Because scientific research in the long-term care population is limited, many recommendations were based on the expert opinion of practitioners in the field.

• American Medical Directors Association (AMDA). Pharmacotherapy companion to the depression clinical practice guideline. Columbia (MD): American Medical Directors Association (AMDA); 2005. 24 p. [12 references]

Not applicable: The guideline was not adapted from another source.

1998 (revised 2005)

American Medical Directors Association - Professional Association

Organizational participants included:

• American Association of Homes and Services for the Aging
• American College of Health Care Administrators
• American Geriatrics Society
• American Health Care Association
• American Society of Consultant Pharmacists
• National Association of Directors of Nursing Administration in Long-Term Care
• National Association of Geriatric Nursing Assistants
• National Conference of Gerontological Nurse Practitioners

Funding was provided by educational grants through Bayer Pharmaceuticals, Eisai, Inc./Pfizer, Eli Lilly & Company, Merck & Company, Novartis Pharmaceuticals, Parke-Davis, and Wyeth-Ayerst Laboratories.

Steering Committee

Members: Marjorie Berleth, MSHA, RNC, FADONA; Susan M. Levy, MD, CMD; Lisa Cantrell, RN, C; Harlan Martin, RPh, CCP, FASCP; Charles Cefalu, MD, MS; Evvie F. Munley; Sandra Fitzler, RN; Jonathan Musher, MD, CMD; Joseph Gruber, RPh, FASCP, CGP; Mary Tellis-Nayak RN, MSN; Larry Lawhorne, MD, CMD; Barbara Resnick, PhD, CRNP; Steven Levenson, MD, CMD; William Simonson, PharmD, FASCP, CGP

Not stated

This is the current release of the guideline.

This guideline updates a previous version: Pharmacotherapy companion to the depression clinical practice guideline. Columbia (MD): American Medical Directors Association; 1998. 26 p.

None available

None available

This summary was completed by ECRI on September 24, 1999. The information was verified by the American Medical Directors Association as of September 27, 1999. This NGC summary was updated by ECRI on August 26, 2005. This summary was updated by ECRI on May 31, 2006 following the U.S. Food and Drug Administration advisory on Paxil (paroxetine hydrochloride). This summary was updated by ECRI on September 7, 2006 following the updated U.S. Food and Drug Administration advisory on Dexedrine. This summary was updated by ECRI on November 22, 2006, following the FDA advisory on Effexor (venlafaxine HCl). This summary was updated by ECRI Institute on November 6, 2007, following the U.S. Food and Drug Administration advisory on Provigil (modafinil) Tablets. This summary was updated by ECRI Institute on November 9, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs.

This NGC summary is based on the original guideline, which is copyrighted by the American Medical Directors Association (AMDA) and the American Health Care Association. Written permission from AMDA must be obtained to duplicate or disseminate information from the original guideline. For more information, contact AMDA at (410) 740-9743.